Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. Stock DD Board Message Board

Amag Pharmaceuticals (AMAG) 23.66 $AMAG AMAG Ph

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 273322
Posted On: 09/03/2016 9:22:41 AM
Avatar
Posted By: Stock_Tracker
Amag Pharmaceuticals (AMAG) 23.66 $AMAG

AMAG Pharmaceuticals to Present at Upcoming Investor Conference
GlobeNewswire - Thu Sep 01, 8:35AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in an analyst-led fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 10:30 a.m. EDT.
AMAG: 23.66 (-0.05), MS: 31.89 (-0.02)

AMAG Pharmaceuticals Rises 1.00% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Aug 22, 4:39PM CDT
AMAG Pharmaceuticals (NASDAQ:AMAG) traded in a range yesterday that spanned from a low of $25.61 to a high of $26.83. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $25.94 on volume of 347,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMAG: 23.66 (-0.05)

After Yesterday's Decline of 8.29%, AMAG Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 10, 1:51PM CDT
AMAG Pharmaceuticals (NASDAQ:AMAG) traded in a range yesterday that spanned from a low of $22.50 to a high of $25.75. Yesterday, the shares fell 8.3%, which took the trading range below the 3-day low of $25.10 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMAG: 23.66 (-0.05)

AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Aug 09, 6:31AM CDT
Total GAAP quarterly product and service revenues increased approximately 50% to $127 million
AMAG: 23.66 (-0.05)

Shares of AMAG Up 27.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 03, 1:12PM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on May 31st, 2016 at $21.22. In approximately 2 months, AMAG Pharmaceuticals has returned 26.96% as of today's recent price of $26.94.
AMAG: 23.66 (-0.05)

How These Healthcare Stocks are Performing? -- AMAG Pharma, IDEXX Laboratories, Neogenomics, and ICON
PR Newswire - Fri Jul 29, 7:50AM CDT
The Healthcare sector remains one of the most stable industries in the market, unfazed by economic conditions and uncertainties. While the industry faces issues with cost pressures, ransomware risks, and existing policies, several companies remain unscathed and continue to impress with significant returns. Stocks to evaluate today on Stock-Callers.com are AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), Neogenomics Inc. (NASDAQ: NEO), and ICON PLC (NASDAQ: ICLR). Learn more about these stocks by accessing their free notes at:
NEO: 8.00 (+0.05), AMAG: 23.66 (-0.05), IDXX: 114.09 (+0.93), ICLR: 77.14 (+0.29)

Should You Get Rid of AMAG Pharmaceuticals (AMAG) Now?
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:54AM CDT
AMAG Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
ANIP: 59.86 (-1.56), AMAG: 23.66 (-0.05)

Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 2.42 (+0.01), AMAG: 23.66 (-0.05), IDXX: 114.09 (+0.93), ALKS: 45.12 (+0.38)

New Strong Sell Stocks for May 19th
Swarup Gupta - Zacks Investment Research - Thu May 19, 7:45AM CDT
5 fresh stock additions to the Zacks Rank #5 (Strong Sell) List for Thursday
UEPS: 9.69 (+0.21), PLM: 0.87 (-0.02), MTGE: 17.34 (+0.33), WY: 31.85 (-0.02), AMAG: 23.66 (-0.05)

AMAG Pharmaceuticals Announces 2016 Analyst Day
GlobeNewswire - Thu May 19, 7:00AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a specialty pharmaceutical company with a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care, today announced that it will host an Analyst Day in New York City on Wednesday, June 1, 2016. The event will start at 8:30 a.m. and conclude at approximately 12:00 p.m. ET.
AMAG: 23.66 (-0.05)

AMAG Pharmaceuticals Has Returned 19.3% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Wed May 18, 1:21AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on May 3rd, 2016 at $23.23. In approximately 2 weeks, AMAG Pharmaceuticals has returned 19.29% as of today's recent price of $18.75.
AMAG: 23.66 (-0.05)

Downgrade Alert for AMAG Pharmaceuticals (AMAG)
Comtex SmarTrend(R) - Thu May 05, 3:36AM CDT
AMAG Pharmaceuticals (NASDAQ:AMAG) was downgraded from Outperform to Market Perform at Raymond James today. The stock closed yesterday at $19.55 on volume of 4.3 million shares, above average daily volume of 1.0 million. AMAG Pharmaceuticals share prices have moved between a 52-week high of $77.73 and a 52-week low of $20.22 and closed yesterday at -3% above that low price at $19.55 per share. Over the past week, the 200-day moving average (MA) has gone down 2.2% while the 50-day MA has declined 0.7%.
AMAG: 23.66 (-0.05)

AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 6:00AM CDT
-- First quarter 2016 non-GAAP product revenue increased 52% to $117.6 million
AMAG: 23.66 (-0.05)

AMAG Pharmaceuticals to Participate in the Deutsche Bank 41st Annual Healthcare Conference
GlobeNewswire - Wed Apr 27, 7:02AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in an analyst-led fireside chat at the Deutsche Bank 41 Annual Healthcare Conference on Wednesday, May 4, 2016 at 8:40 a.m. ET in Boston.
DB: 14.90 (+0.21), AMAG: 23.66 (-0.05)

AMAG Pharmaceuticals to Host Conference Call on May 3, 2016 at 8:00 a.m. ET to Discuss Financial Results for the First Quarter Ended March 31, 2016
GlobeNewswire - Thu Apr 21, 7:03AM CDT
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the first quarter ended March 31, 2016 before the U.S. financial markets open on Tuesday, May 3, 2016. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will provide an update on recent developments and discuss the company's first quarter 2016 financial and operating results.
AMAG: 23.66 (-0.05)

Gilead Presents Multiple HCV and HBV Data at Liver Congress
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 12:59PM CDT
Gilead Sciences (GILD) presented results from several phase II and phase III studies for the treatment of HCV and HBV infection at The International Liver Congress.
EBS: 26.90 (+0.49), GILD: 76.89 (-0.53), AMAG: 23.66 (-0.05), ANIK: 47.89 (-0.05)

Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 10:30AM CDT
Synta (SNTA) announced all-stock merger transaction with Madrigal Pharmaceuticals to create a company focused on cardiovascular-metabolic diseases and NASH.
SNTA: 0.34 (+0.07), EBS: 26.90 (+0.49), ICPT: 150.74 (+3.92), AMAG: 23.66 (-0.05)

Intrexon (XON) Gains Following Deals with Two Startups
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 2:40PM CDT
Intrexon's (XON) shares gained after the company announced exclusive channel collaborations with a couple of Harvest Intrexon Enterprise Fund-backed startups.
EBS: 26.90 (+0.49), FCSC: 0.89 (-0.01), XON: 25.33 (+0.04), AMAG: 23.66 (-0.05)



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us